Established therapies and novel targets in the treatment of Parkinson’s disease
Parkinson’s disease affects more than 1% of individuals older than 60 years of age. The gold standard of its symptomatic treatment is levodopa therapy, which in time leads to motor fluctuations and dyskinesia due to noncontinuous receptor stimulation. Dopamine agonists and monoamine oxidase-B inhibi...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2009
|
| Sorozat: | EXPERT REVIEW OF CLINICAL PHARMACOLOGY
2 No. 6 |
| doi: | 10.1586/ecp.09.47 |
| mtmt: | 1323321 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/10008 |